| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guojun Chen, Paul Chen, Huibing Tan, Da Ma, Fei Dou, Jian Feng, Zhen Ya. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease. Neurobiology of aging. vol 29. issue 12. 2009-01-23. PMID:17555845. |
regulation of the nmda receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of alzheimer's disease. |
2009-01-23 |
2023-08-12 |
mouse |
| Tom Jacobs, Stefaan Rossenu, Adrian Dunne, Geert Molenberghs, Roel Straetemans, Luc Bijnen. Combined models for data from in vitro-in vivo correlation experiments. Journal of biopharmaceutical statistics. vol 18. issue 6. 2009-01-22. PMID:18991117. |
the method is applied to a galantamine controlled release formulation, an acetylcholinesterase inhibitor for the treatment of alzheimer's disease. |
2009-01-22 |
2023-08-12 |
Not clear |
| Dov Barak, Arie Ordentlich, Dana Stein, Qian-Sheng Yu, Nigel H Greig, Avigdor Shafferma. Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. The Biochemical journal. vol 417. issue 1. 2009-01-16. PMID:18729824. |
the role of the functional architecture of the huache (human acetylcholinesterase) in reactivity toward the carbamates pyridostigmine, rivastigmine and several analogues of physostigmine, that are currently used or considered for use as drugs for alzheimer's disease, was analysed using over 20 mutants of residues that constitute the interaction subsites in the active centre. |
2009-01-16 |
2023-08-12 |
human |
| M Weinstock, E Grone. Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18457821. |
the rate and duration of inhibition of recombinant human acetylcholinesterase (ache) and human butyrylcholinesterase (buche) by nine n-methyl,n-alkyl derivatives of (r)-3-prop-2-ynylamino-indan, designed as potential treatment of alzheimer's disease, was obtained from measurement of the carbamylation k(i) and decarbamylation k(3) rate constants. |
2008-12-10 |
2023-08-12 |
human |
| Sadaharu Kotani, Toshihiko Yamauchi, Tetsuyuki Teramoto, Hiroo Ogur. Donepezil, an acetylcholinesterase inhibitor, enhances adult hippocampal neurogenesis. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18501884. |
donepezil hydrochloride is a potent and selective acetylcholinesterase inhibitor and has been treated for alzheimer's disease, in which the cholinergic dysfunction is observed. |
2008-12-10 |
2023-08-12 |
rat |
| María-Salud García-Ayllón, María-Ximena Silveyra, Javier Sáez-Valer. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18554581. |
association between acetylcholinesterase and beta-amyloid peptide in alzheimer's cerebrospinal fluid. |
2008-12-10 |
2023-08-12 |
Not clear |
| María-Salud García-Ayllón, María-Ximena Silveyra, Javier Sáez-Valer. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18554581. |
the altered expression of acetylcholinesterase (ache) in the brains of patients with alzheimer's disease (ad) has raised much interest of late. |
2008-12-10 |
2023-08-12 |
Not clear |
| S Akasofu, M Kimura, T Kosasa, K Sawada, H Ogur. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18571635. |
donepezil is a potent acetylcholinesterase inhibitor used for the treatment of alzheimer's disease. |
2008-12-10 |
2023-08-12 |
rat |
| S Akasofu, M Kimura, T Kosasa, K Sawada, H Ogur. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18571635. |
although acetylcholinesterase inhibitors are thought to be symptomatic treatment of alzheimer's disease, it is not clear whether they are effective against progressive degeneration of neuronal cells. |
2008-12-10 |
2023-08-12 |
rat |
| H Q Lin, Michelle T Ho, Lesley S Lau, Kelvin K Wong, P C Shaw, David C C Wa. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease. Chemico-biological interactions. vol 175. issue 1-3. 2008-12-10. PMID:18573242. |
at present, acetylcholinesterase inhibitors (achei) are the first group of drugs approved by the fda to treat mild to moderate alzheimer's disease. |
2008-12-10 |
2023-08-12 |
Not clear |
| Paul F Boston, Kishore Gopalkaje, Leigh Manning, Lance Middleton, Martin Loxle. Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study. International journal of geriatric psychiatry. vol 23. issue 4. 2008-11-25. PMID:17702052. |
developing a simple laboratory test for alzheimer's disease: measuring acetylcholinesterase in saliva - a pilot study. |
2008-11-25 |
2023-08-12 |
Not clear |
| Maria Laura Bolognesi, Anna Minarini, Michela Rosini, Vincenzo Tumiatti, Carlo Melchiorr. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. Mini reviews in medicinal chemistry. vol 8. issue 10. 2008-11-17. PMID:18782050. |
from dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (mtdls): a step forward in the treatment of alzheimer's disease. |
2008-11-17 |
2023-08-12 |
Not clear |
| Abraham Fishe. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 5. issue 3. 2008-11-05. PMID:18625455. |
the only prescribed drugs for treatment of alzheimer's disease (ad) are acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine, and tacrine) and memantine, an nmda antagonist. |
2008-11-05 |
2023-08-12 |
Not clear |
| D Muñoz-Torrer. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Current medicinal chemistry. vol 15. issue 24. 2008-10-31. PMID:18855672. |
acetylcholinesterase inhibitors as disease-modifying therapies for alzheimer's disease. |
2008-10-31 |
2023-08-12 |
Not clear |
| Aleksandra Siwicka, Zuzanna Moleda, Krystyna Wojtasiewicz, Anna Zawadzka, Jan K Maurin, Mirosława Panasiewicz, Tadeusz Pacuszka, Zbigniew Czarnock. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity. Journal of pineal research. vol 45. issue 1. 2008-10-28. PMID:18284552. |
the compounds obtained possess the 2,3,8,8a-tetrahydropyrrolo[2,3-b]indole heterocyclic system which is a structural motif characteristic of alkaloids, physostigmine and phenserine, that are potent acetylcholinesterase (ache) and butyrylcholinesterase (bche) inhibitors used in the alzheimer's disease treatment. |
2008-10-28 |
2023-08-12 |
human |
| Yu-Wei Liu, Jia-Lie Luo, Hong Ren, Robert W Peoples, Yong-Xun Ai, Li-Jiang Liu, Yuan-Ping Pang, Zhi-Wang Li, Yi-Fan Han, Chao-Ying L. Inhibition of NMDA-gated ion channels by bis(7)-tacrine: whole-cell and single-channel studies. Neuropharmacology. vol 54. issue 7. 2008-10-14. PMID:18407299. |
bis(7)-tacrine is a novel dimeric acetylcholinesterase inhibitor derived from tacrine, and has been proposed as a promising agent to treat alzheimer's disease. |
2008-10-14 |
2023-08-12 |
rat |
| Mohammad A Kamal, Xianqin Qu, Qian-Sheng Yu, David Tweedie, Harold W Holloway, Yazhou Li, Yi Tan, Nigel H Grei. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. Journal of neural transmission (Vienna, Austria : 1996). vol 115. issue 6. 2008-10-03. PMID:18235987. |
synaptic loss, particularly related to the forebrain cholinergic system, is considered to be an early event that leads to alzheimer's disease (ad) and has led to the development of acetylcholinesterase inhibitors (ache-is) as the mainstay of treatment for several degenerative disorders that culminate in dementia. |
2008-10-03 |
2023-08-12 |
human |
| J-F Dartigues, M Ponce. [Treatment of Alzheimer's disease with acetylcholinesterase inhibitors]. Revue neurologique. vol 164 Spec No 2. 2008-09-25. PMID:18680827. |
[treatment of alzheimer's disease with acetylcholinesterase inhibitors]. |
2008-09-25 |
2023-08-12 |
Not clear |
| Michela Rosini, Elena Simoni, Manuela Bartolini, Andrea Cavalli, Luisa Ceccarini, Nicoleta Pascu, David W McClymont, Andrea Tarozzi, Maria L Bolognesi, Anna Minarini, Vincenzo Tumiatti, Vincenza Andrisano, Ian R Mellor, Carlo Melchiorr. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. Journal of medicinal chemistry. vol 51. issue 15. 2008-09-08. PMID:18605718. |
inhibition of acetylcholinesterase, beta-amyloid aggregation, and nmda receptors in alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. |
2008-09-08 |
2023-08-12 |
Not clear |
| Debby Van Dam, Katrien Coen, Peter Paul De Dey. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology. vol 197. issue 1. 2008-08-29. PMID:18008065. |
the interest for acetylcholinesterase inhibitors in the treatment of alzheimer's disease has been greatly renewed owing to the discovery of a broad range of additional cholinergic and non-cholinergic effects, exploitable to maximize the efficacy of these drugs beyond merely improving intellectual functions at the symptomatic level. |
2008-08-29 |
2023-08-12 |
mouse |